CN105396144B - 在肿瘤中差异表达的基因产物及其用途 - Google Patents

在肿瘤中差异表达的基因产物及其用途 Download PDF

Info

Publication number
CN105396144B
CN105396144B CN201510846314.8A CN201510846314A CN105396144B CN 105396144 B CN105396144 B CN 105396144B CN 201510846314 A CN201510846314 A CN 201510846314A CN 105396144 B CN105396144 B CN 105396144B
Authority
CN
China
Prior art keywords
tumor
nucleic acid
antibody
tpte
associated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201510846314.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105396144A (zh
Inventor
U·萨因
O·图里斯
M·科斯洛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Byrne Technologies Europe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byrne Technologies Europe Inc filed Critical Byrne Technologies Europe Inc
Publication of CN105396144A publication Critical patent/CN105396144A/zh
Application granted granted Critical
Publication of CN105396144B publication Critical patent/CN105396144B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
CN201510846314.8A 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途 Expired - Lifetime CN105396144B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10211088.3 2002-03-13
DE10211088A DE10211088A1 (de) 2002-03-13 2002-03-13 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CNA038074931A CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA038074931A Division CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Publications (2)

Publication Number Publication Date
CN105396144A CN105396144A (zh) 2016-03-16
CN105396144B true CN105396144B (zh) 2019-08-20

Family

ID=27771250

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201310025680.8A Expired - Lifetime CN103251952B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN03807493.1A Expired - Lifetime CN1646692B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN201510846314.8A Expired - Lifetime CN105396144B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CNA038074931A Granted CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201310025680.8A Expired - Lifetime CN103251952B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN03807493.1A Expired - Lifetime CN1646692B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA038074931A Granted CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Country Status (14)

Country Link
US (8) US7429461B2 (enExample)
EP (18) EP2311860B1 (enExample)
JP (5) JP4963778B2 (enExample)
KR (4) KR20120127536A (enExample)
CN (4) CN103251952B (enExample)
AU (2) AU2003219045B2 (enExample)
CA (3) CA2478413C (enExample)
DE (1) DE10211088A1 (enExample)
ES (3) ES2559079T3 (enExample)
IL (4) IL163900A0 (enExample)
MX (1) MXPA04008867A (enExample)
NZ (1) NZ535146A (enExample)
PL (1) PL215160B1 (enExample)
WO (1) WO2003076631A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2015201737B2 (en) * 2003-09-26 2016-09-15 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP5089173B2 (ja) 2005-01-07 2012-12-05 独立行政法人理化学研究所 一塩基多型を用いた炎症性疾患の判定方法
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP2083852B1 (en) 2006-10-04 2014-12-10 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
CN105992639B (zh) 2014-03-21 2019-04-16 托普索公司 催化剂支座的免衬垫栅格模块及其模块化系统
MX2017007636A (es) 2014-12-09 2018-03-28 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
CN110734925B (zh) * 2018-07-20 2023-04-07 上海市免疫学研究所 一种粒细胞或单核细胞标记系统及其标记方法和应用
WO2021142349A1 (en) * 2020-01-09 2021-07-15 Deka Biosciences, Inc. Method of using genetic markers, snps and/or indels to determine responsiveness to il-10 treatment
CA3260041A1 (en) 2022-06-30 2024-01-04 Kmc Kartoffelmelcentralen Amba STARCH-BASED GELATIN REPLACEMENTS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8192987A (en) * 1986-12-01 1988-06-16 Northwestern University Human ldh-c4 cdna sequences encoding antigenic regions
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
WO1997026001A1 (en) * 1996-01-16 1997-07-24 Northwestern University Proteins and peptides for contraceptive vaccines and fertility diagnosis
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CA2320427A1 (en) * 1998-02-12 1999-08-19 Incyte Pharmaceuticals, Inc. Human receptor proteins
WO1999060161A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging colon cancer
US6440663B1 (en) * 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
WO2001009315A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel gene participating in the maintenance of smooth muscle cell differentiation
WO2001009316A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel genes encoding protein kinase/protein phosphatase
DE19936563A1 (de) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001229340A1 (en) * 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU3087801A (en) * 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002010363A2 (en) 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20040058341A1 (en) * 2001-07-26 2004-03-25 Y.Tom Tang Protein phosphatases
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5565375B2 (ja) 2011-05-12 2014-08-06 三菱電機株式会社 入退室管理装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A testis-specific gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps to the pericentromeric region of human chromosomes 21 and 13, and to chromosomes 15, 22, and Y;Chen H et al.;《Hum Genet.》;19991130;第105卷;第399–409页
Genomic structure of a copy of the human TPTE gene which encompasses 87 kb on the short arm of chromosome 21;Michel Guipponi et al.;《Hum Genet》;20000801;第107卷;第129页左栏第1段，图1

Also Published As

Publication number Publication date
EP2287181A2 (de) 2011-02-23
US20170101479A1 (en) 2017-04-13
KR20120127536A (ko) 2012-11-21
IL163900A (en) 2015-07-30
IL244596A0 (en) 2016-04-21
EP2314611A2 (de) 2011-04-27
JP2013172716A (ja) 2013-09-05
EP2277907A3 (de) 2011-05-25
EP2311862A3 (de) 2011-07-13
US9637794B2 (en) 2017-05-02
EP1483389A2 (de) 2004-12-08
EP2311861A2 (de) 2011-04-20
US7429461B2 (en) 2008-09-30
CN103251952B (zh) 2018-11-09
EP2289910A2 (de) 2011-03-02
AU2008258158A1 (en) 2009-01-15
AU2003219045A1 (en) 2003-09-22
JP2010047597A (ja) 2010-03-04
EP2332973A2 (de) 2011-06-15
KR20040095283A (ko) 2004-11-12
KR20110117735A (ko) 2011-10-27
CA2813780C (en) 2019-05-07
EP2311860A2 (de) 2011-04-20
JP5756073B2 (ja) 2015-07-29
CA2478413A1 (en) 2003-09-18
EP2277906A3 (de) 2011-05-25
KR20110026529A (ko) 2011-03-15
EP2277901A2 (de) 2011-01-26
EP2277904A3 (de) 2011-06-08
AU2008258158A8 (en) 2009-01-29
EP2277903A3 (de) 2011-05-25
EP2277902A2 (de) 2011-01-26
ES2559079T3 (es) 2016-02-10
US20120014948A1 (en) 2012-01-19
US20150031025A1 (en) 2015-01-29
IL235085A (en) 2016-06-30
CA3035543C (en) 2025-09-23
US8716455B2 (en) 2014-05-06
WO2003076631A3 (de) 2004-06-24
WO2003076631A2 (de) 2003-09-18
US20130243796A1 (en) 2013-09-19
EP2277905A2 (de) 2011-01-26
MXPA04008867A (es) 2005-06-17
EP2314612A3 (de) 2011-08-03
EP2332973A3 (de) 2011-09-07
EP2314611A3 (de) 2011-07-20
EP2277907A2 (de) 2011-01-26
KR101261887B1 (ko) 2013-11-06
ES2685053T3 (es) 2018-10-05
EP2311861A3 (de) 2011-07-13
EP2277901A3 (de) 2011-05-25
EP2289910A3 (de) 2011-06-15
CA2478413C (en) 2020-03-10
EP2287182A3 (de) 2011-06-15
EP2277902A3 (de) 2011-05-25
US9453260B2 (en) 2016-09-27
CN105396144A (zh) 2016-03-16
EP2287181A3 (de) 2011-06-15
EP2311860B1 (de) 2016-09-07
JP5793158B2 (ja) 2015-10-14
PL215160B1 (pl) 2013-10-31
US20090081215A1 (en) 2009-03-26
EP2314610A3 (de) 2011-07-20
EP2311860A3 (de) 2011-07-20
CN1646692B (zh) 2015-12-16
EP2277906A2 (de) 2011-01-26
EP2311862A2 (de) 2011-04-20
NZ535146A (en) 2006-06-30
US20060013817A1 (en) 2006-01-19
AU2003219045B2 (en) 2008-09-18
EP2287182A2 (de) 2011-02-23
US8551490B2 (en) 2013-10-08
EP2287182B1 (de) 2018-08-29
EP2314612A2 (de) 2011-04-27
JP4963778B2 (ja) 2012-06-27
US20160002738A1 (en) 2016-01-07
CN103251952A (zh) 2013-08-21
DE10211088A1 (de) 2003-09-25
PL373384A1 (en) 2005-08-22
IL163900A0 (en) 2005-12-18
JP2005519608A (ja) 2005-07-07
CA2813780A1 (en) 2003-09-18
EP2277905A3 (de) 2011-05-25
US20090081214A1 (en) 2009-03-26
JP2013055938A (ja) 2013-03-28
EP2314610A2 (de) 2011-04-27
EP1483389B1 (de) 2015-11-04
EP2314610B1 (de) 2015-08-26
EP2277903A2 (de) 2011-01-26
ES2688186T3 (es) 2018-10-31
JP5711711B2 (ja) 2015-05-07
CA3035543A1 (en) 2003-09-18
EP2289910B1 (de) 2018-08-08
CN1646692A (zh) 2005-07-27
JP2013081462A (ja) 2013-05-09
EP2277904A2 (de) 2011-01-26

Similar Documents

Publication Publication Date Title
JP5793158B2 (ja) 腫瘍において示差的に発現される遺伝子産物およびこの使用
JP5711698B2 (ja) 腫瘍において示差的に発現される遺伝子産物およびこの使用
AU2012216265B2 (en) Genetic products differentially expressed in tumors and use thereof
HK1153489A (en) Differential in tumour gene products and use of same
HK1153487A (en) Differential in tumour gene products and use of same
HK1154593A (en) Differential in tumour gene products and use of same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Germany Mainz

Applicant after: Ghanimede Pharmaceutical Co.,Ltd.

Address before: Germany Mainz

Applicant before: GANYMED PHARMACEUTICALS AG

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20190422

Address after: Germany Mainz

Applicant after: BIONTECH AG

Address before: Germany Mainz

Applicant before: Ghanimede Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20190820

CX01 Expiry of patent term